賽升藥業(300485.SZ):擬與華放天實簽署K11項目臨牀期間藥學研究及BLA申報服務合同
格隆匯9月10日丨賽升藥業(300485.SZ)公佈,公司(“受讓方”)於2021年9月10日召開的第四屆董事會第九次會議審議通過了《關於簽訂合作協議暨關聯交易的議案》,公司擬與北京華放天實生物製藥有限責任公司(“華放天實”)簽署《K11項目臨牀期間藥學研究及BLA申報服務合同》。公司委託華放天實進行K11抗體藥物從技術轉移開始全面系統的研究、臨牀樣品生產、BLA申報一站式服務,並支付研究開發經費。經費總額為3932萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.